ReviewAmerican journal of hematology2023
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception.
Review in American journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.Nature cancer · 2024Trial
- Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.Haematologica · 2026Article
- Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case-Control Study in Australia.International journal of cancer · 2026Article
- The association between allostatic load and monoclonal gammopathy of undetermined significance (MGUS).British journal of haematology · 2026Article
- Diagnosis, risk stratification and management of smouldering multiple myeloma.Nature reviews. Clinical oncology · 2026Review
- Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma.Blood advances · 2025Article
- Advancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Review
- Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma.Blood advances · 2025Article
- Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma.Annals of hematology · 2025Article
- Deep immune cell profiling in blood and bone marrow of early stage monoclonal gammopathy: an iStopMM and ECRIN-M3 collaborative study.Blood cancer journal · 2025Article
- Review
- Secondary antibody deficiencies: what's around the corner?Frontiers in immunology · 2025Review
- Interferon gamma-mediated prevention of tumor progression in a mouse model of multiple myeloma.HemaSphere · 2024Article
- Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.Blood cancer journal · 2024Article
- Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.Haematologica · 2024Article
- Article
- Next-Generation Therapies for Multiple Myeloma.Annual review of cancer biology · 2024Article
- Immune status and selection of patients for immunotherapy in myeloma: a proposal.Blood advances · 2024Review
- Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy.Haematologica · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined significance (MGUS) are distinct disorders that likely originate in the setting of chronic immune activation. Evolution of these lesions is impacted by cross-talk with both innate and adaptive immune systems of the host. Harnessing the immune system may, therefore, be an attractive strategy to prevent clinical malignancy. While clinical MM is characterized by both regional and systemic immune suppression and paresis, immune-based approaches, particularly redirecting T cells have shown remarkable efficacy in MM patients. Optimal application and sequencing of these new immune therapies and their integration into clinical MM management may depend on the underlying immune status, in turn impacted by host, tumor, and environmental features. Immune therapies carry the potential to achieve durable unmaintained responses and cures in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.